Form 4: Fairmount Funds Converts Preferred Stock to Common Stock in Cogent Biosciences Following Shareholder Approval

Fairmount Funds Management LLC converted 1,500 shares of Series B Convertible Preferred Stock into 1,500,000 shares of Common Stock of Cogent Biosciences after the company's stockholders approved an amendment to increase the number of authorized shares.

Summary

• Fairmount Funds Management LLC, a reporting person, filed a Form 4 detailing changes in beneficial ownership of Cogent Biosciences, Inc. (COGT).
• On June 10, 2024, Fairmount Healthcare Fund II LP converted 1,500 shares of Series B Convertible Preferred Stock into 1,500,000 shares of Common Stock.
• This conversion was triggered by the approval of Cogent Biosciences' stockholders on June 5, 2024, to increase the number of authorized shares of Common Stock from 150,000,000 to 300,000,000.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the securities held by Fund II but disclaim beneficial ownership except to the extent of their pecuniary interest.
• Peter Harwin, a Managing Member of Fairmount Funds Management LLC, serves on the board of directors of Cogent Biosciences, potentially making the Reporting Person a director by deputization.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a conversion of stock. The underlying event is generally positive as it simplifies the capital structure and provides flexibility, hence the score.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Cogent Biosciences.
• Increased authorized shares provide Cogent Biosciences with greater flexibility for future financing or strategic initiatives.

Risks

• The conversion of preferred stock to common stock could potentially dilute existing shareholders' ownership if more shares are issued in the future.

Future Outlook

The document does not contain specific forward-looking statements about Cogent Biosciences' future performance or guidance.

Industry Context

This conversion is a fairly standard corporate action following shareholder approval for increasing authorized shares, allowing for greater flexibility in capital management. Many biotech companies use preferred stock as a financing tool, and converting it to common stock can be a natural progression as the company matures.

Comparison to Industry Standards

• Similar conversions are common in the biotech industry, especially after a company achieves certain milestones or requires more flexibility in its capital structure.
• Companies like Amgen and Gilead have also used convertible preferred stock in the past for financing purposes, later converting them into common stock as their financial positions improved.
• The conversion ratio of 1,000 shares of common stock per share of preferred stock is within the typical range for such transactions.

Stakeholder Impact

• Existing shareholders may experience slight dilution due to the increase in the number of common shares.
• The conversion simplifies the capital structure, which can be viewed positively by investors.

Key Dates